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Abstract Few studies have explored the patterns of clonal
evolution in gliomas. Here, we investigate the cytogenetic
patterns of intratumoral clonal evolution of gliomas and their
impact on tumor histopathology and patient survival. Cytoge-
netic analysis of 90 gliomas was performed in individual tumor
cells (>200 cells/tumor) using multicolor (N=16 probes)
interphase—FISH. Overall, chromosome gains were more
frequent than chromosome losses. Gains of chromosome 7
and/or EGFR amplification were detected in 91% of the cases,
whereas del(9p21) (77%) and del(10q23) (78%) were the
most frequent chromosome losses. Virtually, all cases (99%)
showed ≥2 tumor cell clones, with higher numbers among
high- versus low-grade gliomas (p=0.001). Nine different
cytogenetic patterns were found in the ancestral tumor clones.
In most gliomas, ancestral clones showed abnormalities of
chromosome 7, 9p, and/or 10q and cytogenetic evolution
consisted of acquisition of additional abnormalities followed
by tetraploidization. Conversely, early tetraploidization was
associated with low-grade astrocytomas—2/3 pilocytic and 3/
6 grade II diffuse astrocytomas—and combined loss of 1p36/
19q13 with oligodendrogliomas, respectively; both aberra-
tions were associated with a better patient outcome (p=0.03).
Overall, our results support the existence of different path-
ways of intratumoral evolution in gliomas
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Diffuse gliomas are the most common subtype of primary
brain neoplasms in adults, accounting for around three
quarters of all malignant, central nervous system tumors [1,
2]. Current classification of gliomas is based on morpholog-
ical evidence of differentiation along the astrocytic (~70% of
the cases) or less frequently, oligodendroglial, ependymal, or
mixed cell lineages, and the histopathological degree of
malignancy with >80% of all diffuse gliomas being high-
grade (grade III/IV) tumors [3, 4]. Despite significant
advances in standard treatment modalities, the overall
prognosis of patients with gliomas remains dismal [5, 6];
however, a significant variation is observed in survival of
individual patients [7–9], which cannot be explained just on
the basis of tumor histopathology [10, 11]. In fact, in addition
to tumor grade and the histopathological subtype, other
factors such as patient’s age and cytogenetics, are also
recognized to be useful parameters in predicting patient
outcome and survival [5, 9, 12–14].
At present it is well recognized that gliomas are genetically
highly heterogeneous tumors, even within a single histopath-
ological category [15, 16]. Many studies have been reported
so far, in which cytogenetic and molecular changes
associated with human gliomas have been identified using
different techniques [14, 17–21]. Among other alterations,
the most frequently detected molecular abnormalities include
gains of chromosome 7—with or without amplification of
the epidermal growth factor receptor (EGFR) gene— deletion
and mutation of TP53, alteration of the retinoblastoma
pathway involving the RB1 gene localized at chromosome
13q14, together with losses of the PTEN gene and
hemizygous/homozygous deletion of the p16 tumor suppres-
sor gene at chromosomes 10q23 and 9p21, respectively [14,
22–26]. To date, two distinct, mutually exclusive molecular
profiles have been identified, which would correspond to
either de novo (primary) or secondary glioblastomas devel-
oping after progression of either a low-grade or an anaplastic
astrocytoma [27, 28]. Accordingly, while primary glioblas-
tomas show higher frequencies of p16 deletion, EGFR
amplification and PTEN mutation with a relatively low
frequency of TP53 abnormalities, secondary glioblastomas
more frequently carry mutations of TP53 in association with
abnormalities of the EGFR, p16, and PTEN genes [28, 29].
Despite this, no study has been reported so far in which the
major pathways of acquisition of genetic abnormalities are
systematically analyzed in glioma patients, at the intra-
tumoral cell level [8, 30].
In the present study we have applied multicolor inter-
phase fluorescence in situ hybridization (iFISH) for the
analysis of multiple combinations of 16 different probes
specific for DNA sequences of the most frequently altered
chromosome regions, to gain insight into the intratumoral
cytogenetic heterogeneity of human gliomas at the single
cell level. Our major goal was to define the different
patterns of intratumoral clonal evolution that could contrib-
ute to the identification of those genetic profiles involved in
determining the histopathological features of the tumor.
Materials and methods
Patients and samples
In the present study, tumors from 90 patients —46 males
(51%) and 44 females (49%)—diagnosed with gliomas at
the Neurosurgery Service of the University Hospital of
Coimbra (Portugal), were analyzed. Mean age at diagnosis
was 58±16 years (range, 21 to 84 years). In all tumors,
histological diagnosis and classification were performed
according to the WHO criteria [3] with the following
distribution: 72 cases (80%) were astrocytomas (three grade
I pilocytic astrocytomas, six were grade II diffuse astrocy-
tomas, two corresponded to grade III anaplastic astrocyto-
mas, 61 were grade IV primary or de novo glioblastomas,
and two corresponded to grade IV gliosarcomas), 12 cases
(13%) corresponded to oligodendrogliomas (four grade II
oligodendrogliomas and eight grade III anaplastic oligo-
dendrogliomas), four cases (4%) were oligoastrocytomas
(one grade II oligoastrocytoma and three grade III anaplas-
tic oligoastrocytomas), and, finally, two cases (2%) were
diagnosed as ependymomas (one grade II ependymoma and
one grade III anaplastic ependymoma).
All samples were obtained after informed consent was
given by the patient and the study was approved by the Ethics
Committee of the University Hospital of Coimbra. In all cases,
tumor samples were obtained by conventional surgical
procedures and cut into several parts. Only those tumor tissue
samples shown by gross and histologic inspection to be
mostly or wholly tumor were used to prepare single cell
suspensions for further iFISH studies. Preparation of single
cell suspensions was prospectively done by mechanical
disaggregation of fresh tumor tissue samples. Tissue areas
mirror-cut to those used for iFISH analysis of single cell
suspensions showed always >65% of infiltrating tumor cells;
the remaining cells corresponded to dead cells and eventually
a few proportion of normal brain and leukocyte contamination
(<5%), as assessed by microscopical analysis of hematoxylin
and eosin-stained tissue specimens. Once obtained, single
tumor cell suspensions were stored at −20°C until further
processed. The remaining tumor sample was fixed in formalin
and embedded in paraffin.
For each case, information about the histological character-
istics of the tumor as well as the most relevant clinical and
biological data (e.g., age, gender, and tumor localization) was
recorded.
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Interphase fluorescence in situ hybridization studies
Thirteen genes (TP73, ANGPTL1, EGFR, ELN, TES, p16,
ABL1, PTEN, Rb1, TP53, ZNF44, GLTSCR1, and BCR) and
three chromosome centromeres (chromosomes 7, 9, and 10)
were tested by iFISH (Supplementary Table 1). In all cases,
iFISH analyses were performed on freshly frozen tumor cells
after fixation in 3/1 methanol/acetic (v/v; Panreac, Barcelona,
Spain) with the following commercially available probes—
all obtained from Vysis, Inc. (Downers Grove, IL), except
the 7p12 (EGFR) /alphasatellite 7 DNA dual-color probe that
was obtained from Q-BIOgene (Carlsbad, CA)—which were
systematically used in double-stainings for the detection of
numerical abnormalities of 16 different chromosome regions
(please see Supplementary Table 1 for more detailed
information about the probes used): (1) for chromosome 1,
the LSI 1p36/LSI 1q25 dual-color probe was used; (2) for
chromosome 19, the LSI 19q13/LSI 19p13 dual-color probe
was employed; (3) for chromosome 7, the LSI ELN/LSI
7q31 dual-color probe was applied; (4) for chromosomes 9
and 22, the LSI bcr/abl ES dual-color probe was used; (5) in
addition, also for chromosome 9, the LSI 9p21/CEP-9 dual-
color probe was used; and (6) for chromosome 10, the LSI
PTEN/CEP-10 dual-color probe, was employed. For chro-
mosomes 13 and 17, the LSI Rb1 and LSI p53 probes
conjugated with spectrum orange (SO) were used, respec-
tively. In order to accurately define the exact abnormalities
carried by different tumor cell clones within a tumor sample,
further appropriate multicolor stainings simultaneously using
up to three different probes were performed whenever
required, as illustrated in Fig. 1.
Briefly, fixed tumor cells were dropped onto cleaned, poly-
L-lysine-coated slides (Sigma, St. Louis, MO). The slides
were then sequentially incubated for 10 min at 37°C with a
solution containing 0.1 mg/ml of pepsin (Sigma), fixed in 1%
acid-free formaldehyde (CH2O; Merck, Darmstadt, Germany)
in phosphate-buffered saline for 10 min at room temperature
and dehydrated in increasing concentrations of ethanol
(Merck) in water (70%, 90%, and 100%). Once dried, the
slides containing both the cells’ DNA and the probes’ DNA
were denaturated (6 min at 75°C) and subsequently hybrid-
ized overnight at 38°C in an Hybridizer thermocycler (Dako,
Glostrup, Denmark). Once hybridized, slides were sequential-
ly washed in 50% formamide (Merck) in a 2× saline sodium
citrate (SSC) buffer (10 min at 46°C) and in 2× SSC (5 min at
46°C). Finally, tumor cell nuclei were counterstained with
75 μl of a solution containing 4,6-diamidino-2-phenylindole
(0.1 μg/mL) (Sigma) and Vectashield (Vector Laboratories,
Inc., Burlingame, CA), as anti-fading agent.
An Axioscope fluorescence microscope equipped with a
×100 oil objective (Zeiss, Göttingen, Germany) was used for
counting the number of hybridization spots per nuclei (≥200
nuclei/slide). Only those spots with a similar size, intensity
and shape in non-overlapping nuclei, were counted; doublet
signals were considered as single spots. Cut-offs used to
define the presence of numerical abnormalities for each
individual chromosome, were based on the analysis of normal
human tissue samples, as previously described in detail [31].
Briefly, gains and losses of specific chromosome regions
were considered to occur when ≥5% and ≥10% of the nuclei
showed an increased and decreased number of fluorescent
signals (spots) with respect to normal diploid cells, respec-
tively. Specimens were considered to carry amplification of
the EGFR when more than 10% of the tumor cells exhibited
either an EGFR:CEP7 ratio >2 or multiple tight clusters of
hybridization signals for the EGFR gene probe. Definition of
the exact tumor cell clones present in each sample was based
on the presence of nuclei carrying identical numbers of
hybridization spots for all probes analyzed in that tumor
sample. In this study, only those groups of cells showing
identical cytogenetic profiles which represented ≥5% of the
tumor cells in a sample were considered to be a clone [31].
The ancestral tumor cell clone was identified as that tumor
cell clone which carried genetic abnormalities common to all
other tumor cell clones. In turn, groups of cells carrying
cytogenetic abnormalities not shared by all cytogenetic
altered tumor cells were considered as secondary clones.
Statistical methods
In order to assess the statistical significance of the differences
observed between groups of patients, the Student t and the
Mann–Whitney U tests were used for parametric and non-
parametric continuous variables, respectively; for categorical
variables, the X2 test was applied (SPSS software, SPSS 12.0,
SPSS Inc, Chicago, IL). Overall survival curves were plotted
according to the method of Kaplan–Meier and they were
compared using the log-rank test. p values ≤0.05 were
considered to be associated with statistical significance.
Results
In this study we applied iFISH for the analysis of intratumoral
cytogenetic heterogeneity at the single cell level. This
approach, allowed the identification within individual samples
of distinct cytogenetic profiles. In virtually every case, one or
more chromosomal abnormalities were shared by all clones in
the sample while others were identified in only part of all
tumor cells suggesting they could correspond to earlier vs later
chromosomal changes, respectively (Fig. 1).
Frequency of numerical chromosome changes
Genetic abnormalities for at least one of the 16 different
chromosome probes analyzed (1p36, 1q25, 7p12, 7q11,
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7q31, 9p21, 9q34, 10q23, 13q14, 17p13, 19p13, 19q13,
and 22q11 locus and centromeres of chromosomes 7, 9, and
10) were systematically detected among the 90 gliomas
studied. Overall, chromosome gains were more frequently
observed than chromosome losses (68% vs 51% of all
numerical chromosome abnormalities detected) and includ-
ed all type of polysomies with the presence of three to nine
iFISH signals/cell for individual chromosomes; gene
amplification was only detected for the EGFR gene at
chromosome 7p12 (Fig. 2a). Regarding individual chromo-
somes, chromosomes 7 and 9q34 were the most frequently
altered, and they were gained (including amplification of
the EGFR gene) in 91% and 79% of the tumors,
respectively. Interestingly, gains of chromosome 7 were
found to be associated with deletion of the 7p12 chromo-
some region in six cases (7%), del(7q11) in 12 (13%), del
(7q31) in 16 cases (18%), and loss of centromere 7 in nine
cases (10%). In contrast, gains of chromosome 9q34 were
frequently associated with hemizygous/homozygous dele-
tion of the 9p21 region. Del(9p21) together with del(10q23)
corresponded to the most frequent chromosome losses and
they were identified in around 80% of all cases (77% and
78%, respectively). The frequency of these and other
numerical chromosomal abnormalities detected is detailed
in Fig. 2a.
Intratumoral cytogenetic heterogeneity and hypothetical
pathways of clonal evolution
All except one tumor (99%) showed two or more different
tumor cell clones (number of tumor cells/clone of 5% to 90%)
as defined by the iFISH patterns of cytogenetic abnormalities
detected (Table 1). Presence of two clones was detected in
five cases (6%), three clones in 17 (19%), four in 20 tumors
(22%), five in 17 (19%), and ≥6 tumor cell clones were
found in 30 patients (33%; Table 1). All glioma grades
included tumors which displayed up to four different tumor
cell clones, whereas five and six clones were only observed
among high-grade tumors, with the exception of one grade II
glioma (Table 1).
In 61/90 cases (68%), the cytogenetic aberrations found in
common to all altered tumor cells consisted of abnormalities
of either chromosome 7 (43%) or the short arm of
chromosome 9 (16%) or both (9%; Fig. 2b). Accordingly,
amplification of the EGFR gene was found to be present in
all altered tumor cells (Fig. 3d) of 22% of the cases, while
three to five copies of chromosome 7 (Fig. 3a–c) were found
in all tumor cell clones of 19/90 (21%) cases (Fig. 2b).
Isolated loss of either one or two copies of the 9p21
chromosome region (Fig. 3e, f) was also found to be shared
by all tumor cell clones of 14/90 gliomas (16%; Fig. 2b).
Fig. 1 Illustrating example of how different tumor cell clones were
defined in a glioma using a three-color iFISH staining with probes
directed against the centromeric regions of chromosomes 7, 9, and 17.
As illustrated all nuclei counterstained in blue show gains of
chromosome 7 (green small dots) while this was the only abnormality
for the two nuclei displayed in a it was associated with loss of one
copy of chromosome 9 (red dots) in the four nuclei shown in b and c;
in this latter panel the two nuclei displayed also show loss of one blue
spot (monosomy 17). In turn, the two nuclei in d show duplication of
the fluorescence signals of all three chromosomes analyzed with six,
two, and four copies of chromosomes 7, 9, and 17, respectively.
Arrows indicate the hypothetical model of clonal evolution established
for this tumor based on the abnormalities detected with the three
chromosome probes
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Other cytogenetic aberrations found at lower frequencies in
all tumor cell clones from individual cases included gains of
chromosome 7 in association with hemizygous/homozygous
deletion of the 9p21 chromosome region (9% of the cases),
losses of chromosome 10q (7% of the cases), combined
1p36/19q13 losses (4%), coexisting deletions of several
chromosome regions (12%), and coexisting gains of the
17p13 and 19q13 chromosome regions (2%); in 7% of the
cases the ancestral tumor cell clones were tetraploid, with
several additional changes being found in some of these
tumors (Fig. 2b).
Detailed analysis of the different neoplastic cell clones
present in each glioma tumor pointed out the occurrence of
variable and complex patterns of intratumoral clonal
evolution, as schematically illustrated in Fig. 4 and
Supplementary Fig. 1. As mentioned above, in most cases
(67/90; 74%), numerical chromosomal abnormalities com-
mon to all altered cells from individual tumors involved
chromosomes 7, 9, and/or 10, for a total of five of nine
different cytogenetic profiles (Fig. 4 and Supplementary
Fig. 1). In the other tumors (23/90; 26%), common
abnormalities to all genetically altered cells consisted of
combined loss of the 1p36 and 19q13 chromosome regions
(4/90; 4%), simultaneous losses of several chromosome
regions (11/90; 12%), simultaneous gains of 17p13 and
19q13 (2/90; 2%) or a tetraploid karyotype (6/90 cases;
7%) (Fig. 4). Additional cytogenetic changes to those listed
above and shared by all altered cells were highly variable
Fig. 2 Overall frequency of
different gains and losses of
specific chromosome regions
detected in glioma tumors (a)
and distribution of the tumors
according to the cytogenetic
profile of the ancestral tumor
cell clone (b; n=90). Different
tumors presented with distinct
genetic alterations; in some
cases a mixture of different
abnormalities for the same
chromosome was detected. In
addition, it should be empha-
sized that low-grade astrocyto-
mas (n=9) typically showed
gains for all chromosomes ana-
lyzed, which were associated
with a tetraploid ancestral tumor
cell clone among the later cases
(see Table 3); in contrast, low-
grade oligodendrogliomas typi-
cally showed simultaneous l
osses for chromosome 1p and
19q (n=3/4 cases)
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and heterogeneous. Accordingly, as illustrated in more
detail in Supplementary Fig. 1, cases with amplification of
the EGFR gene (20 cases; 22%) systematically displayed
further gains of 7q (10/20 cases) and/or losses of the 10q23
(14/20 cases) in association or not with losses of one or two
copies of the 9p21 region (16/20 cases) and/or loss of 1p36
chromosome region (6/20 cases). In turn, those tumors
which showed gains of chromosome 7 in common to all
tumor cell clones typically showed the presence of del
(10q23) (5/19 cases) and/or del(9p) (2/19 cases) in
association with variable patterns of other chromosome
changes, except for six cases which had tetraploid cells
(Fig. 4 and Supplementary Fig. 1). Cases with all tumor cell
clones found to show isolated gains of +17p/+19q
displayed distinct patterns of acquisition of additional
chromosome gains and losses in each of the clones
(Fig. 4 and Supplementary Fig. 1).
Of note, those cases which had deletions of chromosome
9p in association or not with gains of chromosome 7 in
common to all altered tumor cells, displayed cytogenetic
Fig. 3 Illustrating examples of some of the most frequently detected
chromosomal abnormalities identified in glioma tumor cells by
interphase fluorescence in situ hybridization (iFISH); original magni-
fication ×1,000. In a–c, nuclei (blue background signal)
corresponding to tumors showing gains—trisomy (a), tetrasomy (b),
and pentasomy (c)—of chromosome 7 (red spots) are displayed; in
these panels (a to c) green spots correspond to a chromosome 7
centromeric probe. Amplification of the EGFR locus (7p12) was
found in 20 gliomas (red spots) and it is illustrated in (d) where green
signals also correspond to the fluorescence emissions associated with
a centromeric probe for chromosome 7. e and f show illustrating
examples of two and one tumor cell carrying nul(9p21) and del(9p21),
as revealed by the absence of red spots or the presence of a single red
spot, respectively; these three cells also show two green spots each,
corresponding to a probe directed to the centromeric region of
chromosome 9
Table 1 Glioma tumors (n=90): number of cytogenetically defined tumor cell clones according to the WHO tumor grade
No. of clones/tumor Tumor grade* Total cases
I (n=3) II (n=12) III (n=14) IV (n=61)
1 0/3 (0%) 1/12 (8%) 0/14 (0%) 0/61 (0%) 1/90 (1%)
2 2/3 (67%) 2/12 (17%) 1/14 (7%) 0/61 (0%) 5/90 (6%)
3 1/3 (33%) 5/12 (42%) 6/14 (43%) 5/61 (8%) 17/90 (19%)
4 0/3 (0%) 3/12 (25%) 2/14 (14%) 15/61 (25%) 20/90 (22%)
5 0/3 (0%) 0/12 (0%) 1/14 (7%) 16/61 (26%) 17/90 (19%)
≥6 0/3 (0%) 1/12 (8%) 4/14 (29%) 25/61 (41%) 30/90 (33%)
Results expressed as number of cases/total cases and percentage in brackets
WHO World Health Organization
*p<0.001
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patterns with between one and four additional abnormalities
of chromosomes 1p, 7, 10q, 13q, and 17p; in addition, 3%
of these cases with del(9p21) with or without gains of
chromosome 7 in common to all tumor cell clones, showed
tetraploidization (Fig. 4 and Supplementary Fig. 1). As it
may be inferred from what is describe above, tetraploidiza-
tion with variable losses and gains of one or more
chromosomes was a relatively common finding and it was
detected in secondary clones of around half of the cases
(47/90; 52%), in addition to those cases (7%) that presented
tetraploidy in common to all tumor cell clones (Fig. 4 and
Supplementary Fig. 1). However, in some subgroups such as
cases with combined del(1p) and del(19q), secondary clones
showed multiple additional chromosome losses in the
absence of a tetraploid karyotype (Fig. 4 and Supplementary
Fig. 1)
Interestingly, once gliomas were grouped according to
the cytogenetic profile found to be common to all altered
tumor cells, a longer overall survival was observed (p=0.03)
for cases that displayed either tetraploidy or del(1p)
associated with del(19q) compared to patients who had
abnormalities of chromosome 7, del(9p), del(10q) and
simultaneous gains of chromosome 17p and 19q (Fig. 5).
Cytogenetic profiles and tumor grade
Upon analyzing the frequency of the distinct cytogenetic
abnormalities detected in gliomas according to tumor
histopathology, several remarkable differences were noted
between astrocytic and oligodendroglial, as well as between
grade I/II and grade III/IV cases (Table 2). Accordingly,
astrocytic grade I/II tumors (9/72 cases; 13%) were mainly
characterized by the presence of gains for all chromosome
regions analyzed (including all three astrocytic grade I
tumors) consistent with tetraploidy in five of nine cases. In
contrast, high-grade astrocytic tumors (63/72 tumors; 88%)
showed more complex and heterogeneous genetic alter-
ations, with a significantly higher frequency of chromo-
some abnormalities (Table 2).
Fig. 5 Overall survival curves of gliomas grouped according to the
cytogenetic abnormalities found to be common to all altered tumor
cells. Of note, most (five of six tumors) tetraploid cases corresponded
to low-grade astrocytomas and around half of all tumors showing del
(1p)/del(19q) and/or other multiple losses in their ancestral tumor cell
clone were low-grade gliomas (two diffuse astrocytomas, four
oligodendrogliomas, and one ependimoma out of 15 cases); in
contrast, high-grade gliomas predominated among the other cytoge-
netic groups
Fig. 4 Hypothetical pathways of intratumoral clonal evolution of
gliomas (n=90) defined on the basis of the most frequent cytogenetic
patterns detected for the 16 different chromosome probes analyzed. In
this figure, only the most frequently detected ancestral tumor cell
clones and their corresponding subsequent second clones are
displayed. Noteworthy, most (five of six tumors) tetraploid cases
corresponded to low-grade astrocytomas and around half of all tumors
showing del(1p)/del(19q) and/or other multiple losses in their
ancestral tumor cell clone were low-grade gliomas (two diffuse
astrocytomas, four oligodendrogliomas, and one ependimoma out of
15 cases); in contrast, high-grade gliomas predominated among the
other cytogenetic groups. For more detailed information on the exact


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Interestingly, a significant association was also found
between tumor grade and the iFISH patterns of cytogenetic
abnormalities detected in common to all tumor cell clones
identified in individual cases (Table 3). Accordingly, while
grade I/II astrocytic tumors showed either gains of
chromosome 7 or tetraploidy in common to all altered
tumor cells, high-grade astrocytic tumors (grades III/IV)
revealed more complex cytogenetic patterns, with a
considerable lower frequency of tetraploid tumors (Table 3).
Although the number of cases analyzed for other histo-
pathological subtypes was rather limited, combined loss of
the 1p36 and 19q13 regions was most frequently found in
common to all tumor cell clones in oligodendrogliomas
(4/12 cases; 33%, particularly in low-grade cases, three of
four cases). Despite this, as found in high-grade oligoas-
trocytic tumors, anaplastic oligodendrogliomas, in addition
to 1p36/19q13 losses, showed more heterogeneous cyto-
genetic patterns in common to all tumor cell clones with
respect to oligodendroglial grade II tumors; similarly to
what was observed among high-grade astrocytomas, these
included gains of chromosome 7, losses of the 9p21
chromosome region and other multiple chromosome losses
(Table 3).
Discussion
Until now, few studies have been reported in which the
cytogenetic heterogeneity of glioma tumors is assessed at the
intratumoral cell level [32, 33], and only Lopez-Gines et al.
[34] and Wemmert et al. [33] have used iFISH analyses
based on a limited number of chromosome probes, to assess
clonal evolution in glioblastomas and pilocytic astrocytomas,
respectively. Through the study of 25 glioblastomas Lopez-
Gines et al. [34] suggested that trisomy/polysomy 7 and
monosomy 10 were frequently associated in glioblastomas,
whereas EGFR amplification could represent a later event
not associated with the former profile (gains of chromosome
7/chromosome 10 losses). In turn, Wemmert et al. [33]
confirmed the occurrence of intratumoral cytogenetic het-
erogeneity among 14 pilocytic astrocytomas, through iFISH
analysis of numerical abnormalities for chromosomes 7, 8,
17, and the TP53 gene.
In this study, we used a multicolor iFISH approach aimed at
the investigation of a large number (n=16) of different
chromosome regions, including those more frequently altered
in gliomas, to assess intratumoral genetic heterogeneity in a
series of 90 patients studied at diagnosis. In order to identify
the exact sequence of accumulation of chromosomal abnor-
malities in individual tumors carrying multiple subclones, we
assumed that karyotypic abnormalities shared by all subclones
should represent relatively early changes; in contrast, later











































































































































































































































































































































































































































































































































































































































































other tumor cell clones. In line with this concept of clonal
evolution, our results show that in virtually all gliomas, ≥2
cytogenetically related tumor cell clones which carry different
chromosomal abnormalities, are present.
Overall, nine different cytogenetic profiles were identi-
fied in the ancestral tumor cell clones of the 90 cases
analyzed. These most commonly involved partial or
complete gains of chromosome 7—including amplification
of the EGFR gene—hemizygous or homozygous deletion
of 9p21 and del(10q); interestingly, combinations of such
alterations were either already detected in the ancestral
tumor cell clone or acquired in subsequent, highly
represented clones. Of note, these complex cytogenetic
patterns typically occurred prior to tetraploidization—a
cytogenetic profile detected during evolution of a great
proportion of all tumors analyzed—in the context of a
relatively high number of tumor cell clones/sample and
they were characteristic of high-grade astrocytic tumors.
Altogether, these results clearly show that complex
karyotypes in which combined gains of chromosome 7—
including amplification of the EGFR gene—del(9p21) and/or
del(10q23) coexist, are crucial events for the development of
a great majority of gliomas with an astrocytic phenotype; in
addition, they support previous observations about the role of
combined alterations of the EGFR, p16/p14ARF, and/or PTEN
genes in the malignant (high-grade) transformation of these
tumors [10, 24, 35, 36]. In line with this, it has been
previously shown that most gliomas coexpress the EGFR
and EGF molecules, which are involved in an autocrine loop
of growth stimulation [37]. Of note, EGFR mediates its
cellular effects through the PI3K-Akt pathway [38], which is
repressed by the expression of PTEN [39, 40]; loss/mutation
of this later gene results in a direct increase in cell growth
together with a blockade of apoptosis and up-regulation of
vascular endothelial growth factor production [37, 40, 41].
Similarly, deletion of p16 and p14ARF would also favor cell
proliferation in these tumors, particularly when associated
with mutations or epigenetic silencing of the remaining copy
of these genes [40, 42]. Such a cytogenetic profile consisting
of disruption of the p16–pRb–p14ARF–TP53 cell cycle
control pathways, inactivation of tumor suppressor genes
on chromosome 10 (e.g. PTEN) and amplification of the
EGFR gene, has been associated with high-grade gliomas
with an astrocytic phenotype [40] as also found in our series.
In turn, the higher number of tumor cell clones observed
among high-grade gliomas suggests a high genetic/chromo-
somal instability, which would facilitate the emergence and
sequential selection of more aggressive subclones that would
lead to tumor progression and more aggressive histopatho-
logical features. Of note, this high genetic/chromosomal
instability cannot be therapy-induced since the studied
glioblastoma multiforme are primary (or de novo) GBM,
without any previous treatment.
Other less frequent cytogenetic profiles recurrently ob-
served in the ancestral tumor cell clones included tetraploidy,
combined loss of 1p36/19q13 and combined gains of
chromosomes 17 and 19; while the later pattern was only
found in a few high-grade glioblastomas, the former were
characteristic of low-grade tumors with a better outcome and
an astrocytic or oligodendroglial/mixed phenotype, respec-
tively. In contrast to high-grade gliomas, few cytogenetic
profiles were detected in common to all altered tumor cells in
grade I/II astrocytic tumors. Such profiles were consistent
with tetraploidy and less frequently, with chromosome 7 gains
in the absence of losses of chromosomes 9p21 and 10q23,
immediately followed by tetraploidization in subsequent
tumor cell clones. Based on these observations, it could be
hypothesized that early occurrence of tetraploidization in
association with duplication of the BRAF gene in pylocytic
astrocytomas [43, 44] could prevent histopathological grade
I/II astrocytomas from evolving into an invasive phenotype
and a highly progressive clinical behavior tied to aggressive
histopathological features; this could be due to the fact that
p16/p14ARF and chromosome 10q losses that occur after
tetraploidization would have a more limited impact in the
aggressiveness of the tumor because at least one copy of
each allele of these genes would still be retained. In line with
this, a tetraploidy checkpoint has been associated with
prevention of tumor progression among gliomas [45, 46]
and these cytogenetic profiles were also much less
frequently observed among high-grade gliomas, where
acquisition of multiple cytogenetic abnormalities leading
to relatively complex cytogenetic profiles, typically
preceded tetraploidization. Although early tetraploidization
was associated with a significantly better clinical outcome,
this could be due to its association with low-grade astrocy-
tomas and deserves further multivariate analyses in larges
series of patients to determine its potential independent
prediction value.
Combined losses of 1p36 and 19q13, were detected in
common to all tumor cells in 3/4 (75%) grade II
oligodendrogliomas, while only 1/8 (12%) high-grade
oligodendrogliomas showed this cytogenetic profile in its
ancestral tumor cell clone. At present, the molecular
mechanisms involved in the ontogeny of oligodendroglial
tumors remains largely unclear. However, recent reports
point out the potential involvement of p21 [47], and other
recently identified oligodendroglioma-associated candidate
tumor suppressor genes localized at the 1p36 and 19q13
chromosome regions, in the development of oligodendro-
gliomas [48, 49]. In fact, it has been shown that, del(1p)
and del(19q), as well as translocations involving these
chromosome regions are the genetic hallmark of oligoden-
droglial tumors [50–53] as also found in our series;
however, it should be noted that in line with our findings,
losses of chromosomes 1p and 19q could be less commonly
Neurogenetics
detected in anaplastic/grade III versus grade II oligoden-
drogliomas [3, 49].
Altogether, these results may suggest that while astrocytic
and oligodendroglial tumors may progress [27, 28, 54] from
histologically low- to high-grade tumors, frequently, different
genetic pathways could be involved in histologically low-
versus high-grade gliomas [55]. In line with this hypothesis,
previous studies aimed at dissecting the genetic pathways of
tumor progression through the comparison of the karyotypes
of different histological subgroups of gliomas [4, 9–11] have
pointed out the existence of two clearly distinct cytogenetic
patterns. One corresponds to the majority of cases represent-
ing primary or de novo glioblastomas, which are genetically
characterized by loss/mutation of 10q/PTEN, EGFR ampli-
fication and/or p16 deletion with a low frequency of TP53
mutations. The second cytogenetic pattern is characteristic of
secondary glioblastomas, which develop through progression
from low-grade diffuse astrocytomas or anaplastic astrocy-
tomas where TP53 mutation is the most frequent and earliest
detectable genetic alteration [24, 30]. Our results support and
extend on this hypothesis by showing that, at the intra-
tumoral cell level, early tetraploidization together with
combined 1p36/19q13 losses are associated with low-grade
astrocytomas and oligodendroglial tumors, respectively; of
note, tetraploidy was similarly found in pilocytic grade I as
well as grade II, diffuse astrocytomas as also reported by
others [56, 57]. In contrast, the ancestral tumor cell clones of
high-grade gliomas are more likely associated with early
occurrence of combined gains/amplification of the EGFR
gene in chromosome 7, hemizygous or homozygous del
(9p21) and/or deletion of the PTEN gene in chromosome
10q, followed by acquisition of complex karyotypes prior to
tetraploidization. Based on these observations, it could be
hypothesized that early tetraploidization in gliomas with an
astrocytic phenotype could prevent these tumors from having
an aggressive behavior, even in the presence of TP53
mutation/deletion [40, 58, 59]; in contrast, occurrence of
tetraploidization at relatively advanced stages of the disease,
after gains of chromosome 7/EGFR amplification, del(9p21)
and/or del(10q23) have already occurred, would not have
such an impact. These observations together with the limited
number of low-grade tumors included in our study point out
the need to confirm our observations in larger series of low-
grade gliomas, in which comparative analysis of the
cytogenetic profiles of primary versus secondary high-grade
tumors are also analyzed.
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